Amalus Therapeutics

Amalus Therapeutics is a biotechnology startup based in Belgium, founded in 2023. The company's slogan, "precisely remodeling tissues. profoundly reshaping lives.", reflects its core focus on leveraging selective fibroblast modulation to develop transformative therapeutics. By targeting pathologically activated fibroblasts with unparalleled selectivity, Amalus Therapeutics aims to achieve precise tissue remodeling and normalization, offering multiple therapeutic benefits across Biotechnology and Health Care sectors. In August 2023, the company secured a €500.00K Convertible Note investment from BioInnovation Institute, emphasizing the confidence of investors in Amalus Therapeutics' innovative approach to addressing diseases driven by abnormal tissue structure. The investment signifies a notable endorsement of the company's potential to make a significant impact in the biotechnology and healthcare industries. Amalus Therapeutics' pioneering technology and strategic partnerships position it as a promising player in the space, offering potential for substantial growth and disruptive contributions to medical advancements.